Citations 22
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Kumar, Shaji , LaPlant, Betsy, Reeder, Craig B. , Halvorson, Alese E. , Bergsagel, P. Leif , Thompson, Melanie , Crawley, Jamie , Kapoor, Prashant , Stewart, Keith, Hayman, Suzanne R. , Hwa, Yi L. , Dingli, David , Lin, Yi , Rivera, Candido E., Lacy, Martha Q. , Nahi, Hareth , Bergsagel, P. Leif , Kumar, Shaji K , LaPlant, Betsy R, Mıkhael, Joseph , Roy, Vivek , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Gonsalves, Wilson I. , Witzig, Thomas E. , Ailawadhi, Sikander , Go, Ronald S. , Rajkumar, S. Vincent , Dingli, David , Lin, Yi , Nahi, Hareth
Blood | October 4, 2016 | Volume: 128 | Issue: 20 | Pages: 2415-2422
Key Points The combination of ixazomib and dexamethasone has clinical activity in patients with relapsed and or refractory multiple myeloma. Higher dose of ixazomib leads to improved response rates but with higher rates of treatment related adverse events.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Avet‐Loiseau, Hervé , Dimopoulos, Meletios Α. , Špıčka, Ivan , Masszi, Tamás , Hájek, Roman , Rosiñol, Laura , Mihaylov, Georgi , Maisnar, Vladimír , Mateos, María‐Victoria , Wang, Michael , Niesvizky, Rubén, Oriol, Albert , Minařík, Jiří , Palumbo, Antonio , Bensinger, William, Kukreti, Vishal , Ben‐Yehuda, Dina, Stewart, A. Keith, Obreja, Mihaela, Moreau, Philippe , Nahi, Hareth , Goranova‐Marinova, Veselina , Fonseca, Rafaël , Siegel, David S. , Goranova-Marinova, Vesselina S , Jakubowiak, Andrzej , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , Masszi, Tamas , Nahi, Hareth , Oriol, Albert
Blood | July 21, 2016 | Volume: 128 | Issue: 9 | Pages: 1174-1180
Key Points KRd has a favorable benefit-risk profile compared with Rd, regardless of baseline cytogenetic risk status, in patients with relapsed MM. KRd improves but does not abrogate the poor prognosis associated with high-risk cytogenetics in patients with relapsed MM.